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Abstract: Aims: To evaluate OS and EFS of paediatric sarcoma patients with an interest in comparing metastatic cases 
with non-metastatic cases, and compiling statistics on treatment methods. 
Methods: Information was obtained from patient notes in the Schiehallion ward. These contained information about 
diagnosis, treatment, prognostic indicators, and outcomes for each patient. 
Results: 56 patients, 2001-2008. Osteosarcoma: 11 patients, 7??? ??; age range: 4-16; ?? ????OS = 64%, EFS = 55%; 
Primary site of disease: Femur (47%), Tibia (41%), Humerus (5.5%), Scapula (5.5%), Other (1%); Metastatic Rate = 
27% (OS = 0%). Ewing’s sarcoma: 24 patients, 10??????? age range: 1-16??????; OS = 71%, EFS = 58%; Primary site of 
disease: Pelvis (29%), Femur (22%), Paraspinal (16%), Chest Wall (10%), Tibia (10%), Other (13%); Metastatic Rate = 
21% (OS = 40%; EFS = 40%); Alveolar rhabdomyosarcoma: 10 patients; OS= 80%, EFS = 60%; Metastatic Rate = 20% 
(OS = 100%; EFS = 100%). Embryonal rhabdomyosarcoma: 11 patients; OS = 73%, EFS = 73%; Metastatic Rate = 0%. 
Conclusions: Our results reflect access to an experienced and innovative paediatric sarcoma service with close links to a 
national Sarcoma MDT. The data falls in line with other studies in terms of age of onset, location of primary tumour, 
metastatic rate, site of metastases, and prognosis for all cancer types. Limb salvage surgery is greatly favoured over 
amputation for both osteosarcoma and Ewing’s sarcoma. Females have a more favourable prognosis in osteosarcoma 
and a slightly poorer prognosis in Ewing’s sarcoma. Yorkhill’s overall survival rates are currently better than the UK-wide 
statistic for three of the four tumours examined.  
Keywords: Children, Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Outcome, Glasgow. 
1. INTRODUCTION 
When we compare recent statistics on cancer 
incidence in the UK we see that childhood cancer (0-14 
years) is very rare. There are approximately 143 new 
cases of cancer diagnosed per one million each year of 
the population for this age group [1]. In comparison, the 
age group of teenage and young adults (15-24 years) 
has 272 new cancer diagnoses per one million 
population each year, whereas the incidence rate for 
the combined population of the UK is approximately 
5,242 per one million each year [2,3]. 
Soft tissue sarcomas, that is, neoplasms of 
connective and supportive tissue, account for 
approximately 6.5% of all childhood cancers [4]. Of 
these, more than half are rhabdomyosarcomas [5]. 
Bone cancers account for approximately 10% of all 
malignant neoplasms in children and fall into two main 
categories: osteosarcoma and Ewing’s sarcoma [6]. 
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1.1. Osteosarcoma 
This is an aggressive and highly malignant bone 
tumour that has one of the lowest survival rates for 
children. In the UK, osteosarcoma has an incidence 
rate of about 3 people per one million of the general 
population, and it affects males more than females with 
a ratio of 1.4:1 [7]. Although the cause of the cancer is 
currently unknown, the correlation between age of 
onset and the most common sites of onset – the 
proximal tibia and the distal femur – suggests a 
relationship to maximum osteoblastic activity [8]. There 
are a couple of known genes – the retinoblastoma 
gene and the p53 gene – that have been reported to 
increase susceptibility to development of an 
osteosarcoma [8].  
Osteosarcomas usually form compact, whiteish, 
hard tissue that grows rapidly in a circular-like mass 
towards the periosteal surface, where it can spread to 
adjacent soft tissues. The tumour then often spreads 
through the blood stream and becomes metastatic – 
the most common site being the lungs. The histological 
diagnosis depends on the presence of malignant 
connective tissue stroma with cells that form new bone 
or osteoid [9]. Variants on the basis of histological 
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differences have been identified and include osteo-
blastic, fibroblastic, chondroblastic, and telangiectatic. 
Other variants include intraosseous well-differentiated 
(low-grade), small-cell, multifocal, surface (peripheral), 
para-osteal (juxtacortical), periosteal, and high-grade 
surface [10] (Table 1).  
Table 1:  A study based on 1046 Patients Detailed the 
Skeletal Distribution 
Site Number of patients % 
Femur 521 50  
Tibia 269 26  
Humerus 102 10  
Fibula 54 5  
Pelvis 40 4  
Skull 15 1.5  
Radius 11 1 
Rib 10 1 
Vertebra 9 >1 
Clavicular 4 >1 
Hand 4 >1 
Scapula 3 >1 
Foot 3 >1 
Ulna 1 >1 
Table Adapted from Paediatric Oncology – Clinical Practices and 
Controversies [11].
 
Patients will present with pain, usually gradually 
increasing, with swelling of the affected area becoming 
more prominent. Often, patients and their families will 
associate the pain with a recent sports injury or it may 
be assumed to be caused by simple ‘growing pains’. 
Once they present to hospital, a plain X-ray is normally 
the first diagnostic image taken where a lesion with 
new bone formation will be seen. Often there will be 
breakage of the tumour into the cortex and adjacent 
soft tissue [11]. The initial X-ray image will be 
complemented by CT and/or MRI scanning as well as a 
radionuclide bone scan to gain a description of the 
primary tumour and to detect any metastatic deposits. 
The MRI and bone scan will also be able to detect any 
‘skip’ lesions, that is, tumour deposits in other areas of 
the affected bone, that are known to occur in 
approximately 5% of cases [12].
 
The main sites for 
metastases are the lungs (98%), other bones (37%), 
pleura (33%), and heart (20%) [13] (Table 2). 
In comparison to other cancers, the prognosis for 
osteosarcoma is quite poor. With modern treatment, 
and with patients who have a localised lesion, the 5  
 
year survival rate is somewhere between 60-80% [15]. 
If metastases are present at the time of diagnosis, the 
5 year survival rate drops to between 15-30% [15].  
 
Table 2:  Treatment for Osteosarcoma takes place Over 
a Number of Phases [14] 
Phase 1 Neo-adjuvant chemotherapy: 
Once osteosarcoma has been diagnosed the patient 
is given chemotherapy with the aim of attempting to 
shrink the primary tumour and kill any cancer cells 
that may have metastasised. 
Phase 2 Surgery: 
The aim of surgery is to remove as much of the 
primary surgery as possible whilst keeping the body 
working as best it can. This is much simpler in limbs, 
where either an amputation or limb-salvage surgery 
can be performed, rather than in other places in the 
body such as the pelvis or spine. 
Limb-salvage surgery may be possible using a metal 
implant and false joint, or using an autologous bone 
graft. 
Phase 3 Pathology: 
After surgery, the tumour is examined by a 
pathologist to check if all of it has been removed 
successfully and to see if the chemotherapy drugs 
are having any impact. 
Phase 4 Adjuvant Chemotherapy: 
The patient will then go on to receive a further 
regimen of chemotherapy drugs normally lasting for a 
period of 18 weeks. 
Phase 5 Further Surgery: 
This may be necessary to remove secondary tumours 
that might have spread to other parts of the body. 
 
However, this figure is closer to 40% if the metastases 
are confined to only the lungs or if all tumours, 
including metastases, have been completely removed 
[15]. Chemotherapy is an essential component in 
treatment, especially in high-grade osteosarcomas, 
where without it, the cancer is very likely to recur [15].
 
Certain factors have been linked to a more favourable 
diagnosis, including: 
• being younger 
• being female 
• the primary tumour site being in an arm or leg 
• the tumour being completely resectable 
• normal blood alkaline phosphate levels and LDH 
levels 
• good tumour response to chemotherapy [15] 
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1.2. Ewing’s Sarcoma 
Ewing’s sarcoma is a malignant bone tumour that 
belongs to a family of small round-cell tumours includ-
ing neuroblastoma, poorly differentiated rhabdomyo-
sarcoma, and Askin tumour (primitive neuroectodermal 
tumour – PNET – of the chest wall) [16]. If affects 
slightly less than 2 people per million of the general 
population with a peak incidence between 10 and 20 
years of age [17].
 
Although it is thought of as childhood 
cancer, recent research shows that over half of all 
cases present in patients over the age of 15 [17]. It 
accounts for about 6% of all primary malignant tumours 
in bone and around 40% of all the primary bone 
cancers diagnosed in the young people in the UK 
[16,17].
 
Again, like osteosarcoma, the exact causes of 
Ewing’s sarcoma are unknown but with the peak 
incidence being around the time of most rapid bone 
growth, a link between the two can be deduced.  
Ewing’s sarcoma originates from the intramedullary 
cavity and often breaks through the cortex and extends 
into the surrounding soft tissue [18]. The tumour tissue 
is seen to be a greyish-white with areas of 
haemorrhage and necrosis [18]. Histologically it is 
characterised by densely packed, regularly shaped, 
small cells with round or oval nuclei, often showing 
translocations between chromosomes 11 and 31 [19].
 
The classic differential diagnosis that can mimic 
Ewing’s on radiological imaging is osteomyelitis [20]. 
Other differentials that must be ruled out include 
rhabdomyosarcoma, neuroblastoma, peripheral neuro-
ectodermal tumour (PNET), small-cell osteosarcoma, 
and primary lymphoma of bone [20] (Table 3).  
Table 3:  A Study Based on 300 Patients Demonstrated 
the Distribution of Ewing’s Sarcoma 
Site Number of patients % 
Pelvis 60 20 
Femur 58 19 
Fibula 32 11 
Tibia 31 10 
Rib 30 10 
Vertebra 23 8 
Scapula 19 6 
Foot 7 2 
Ulna 5 1.67 
Clavicular 5 1.67 
Skull 4 1 
Radius 3 1 
Sternum 1 >1 
Table Adapted from Paediatric Oncology – Clinical Practices and 
Controversies [20].
 
Patients will commonly present with pain and 
swelling that may worsen rapidly over a short period of 
time. Again, like osteosarcoma, the first diagnostic 
imaging taken is normally a plain X-ray where a ‘moth-
eaten’ pattern of bone destruction along with a parallel 
‘onion skin’ appearance of new periosteal bone 
formation is seen [16,20]. Pathological fractures will be 
seen in approximately 5% of cases [20]. Further 
imaging in the form of CT or MRI will be undertaken to 
look for the presence of metastases, which, because of 
the highly aggressive nature of the tumour, are very 
common. The estimate of metastases at diagnosis is 
25% [21]. 
Treatment for Ewing’s sarcoma is similar to that of 
osteosarcoma with one major difference: whereas 
osteosarcoma is a very radio-resistant lesion, Ewing’s 
is very radio-sensitive and therefore radiotherapy plays 
a big role. Neo-adjuvant chemotherapy will be 
administered with the aim of shrinking the primary 
tumour and destroying any potential metastatic spread. 
Then surgery will be undertaken, the complications of 
which depend on the site of the primary tumour. If the 
tumour is in one of the limb bones, complete resection 
(either by amputation or by a limb-sparing procedure) 
will be less complicated than if the primary site is in one 
of the flat bones of the body, such as the pelvis. After 
surgery, the removed tumour will be examined by a 
pathologist and the decision to undergo radiotherapy 
will be taken. Radiotherapy will be administered if 
either the whole tumour has not been removed or if 
more than 10% of the tumour remains alive when 
examined under microscope [22].
 
Adjuvant 
chemotherapy will normally continue regardless of 
radiotherapy treatment and further surgery may have to 
be carried out at a later date to remove any metastatic 
spread, for example, in the lungs. 
Overall, the 5-year survival rate for Ewing’s 
sarcoma when the patient has presented with a 
localised tumour is estimated to be around 70% [23]. If 
the patient presents with metastatic disease the 5-year 
survival drops to between 15% and 30% [23].
 
This 
figure is slightly higher if the metastases are only 
confined to the lungs. Other prognostic factors include 
are mentioned in Table 4 [24]. 
1.3. Rhabdomyosarcoma 
Rhabdomyosarcoma is a highly malignant tumour 
that is thought to arise from mesenchymal cells that 
would further develop into striated muscle [25]. Due to 
its  embryological  nature,  they are  the  most common  
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Table 4: Other Prognostic Factors [24] 
Site of tumour 
Distal extremities have the best prognosis with 
central sites such, as the pelvis and sacrum, 
the worst. 
Age 
Patients younger than 15 have a better 
prognosis than those that present after 15 
years of age.  
Gender Girls have a better prognosis. 
Serum lactate 
dehydrogenase 
Increased serum LDH levels at time of 
diagnosis are associated with poorer 
prognosis. 
 
form of malignant soft-tissue tumour in infants and 
young children, accounting for about 3% of all 
childhood cancers [26,27].
 
It shows a peak incidence at 
around three years old [28]. There are four distinct 
types of rhabdomyosarcoma, described in Table 5.  
Table 5: Types of Rhabdomyosarcoma 
Type Features 
Embryonal • along with botryoid rhabdomyosarcoma, 
accounts for approximately two thirds of all 
rhabdomyosarcomas 
• primarily a tumour of early childhood 
• resembles striated muscle 
Botryoid • the term botryoid means ‘grape-like’ and is 
applied to embryonal rhabdomyosarcomas 
with a polypoid configuration and a myxoid 
consistency  
• occurs in mucosa-lined organs 
Alveolar • accounts for about one quarter of 
rhabdomyosarcomas 
• arises in voluntary muscle 
• typically presents between ages of 10-20 years 
Pleomorphic • rarest subtype 
• tends to arise in limbs of both children and 
adults 
Table Adapted from Woolf’s Pathology: Basic and Systemic [29]. 
Although the exact cause of rhabdomyosarcoma is 
unknown, there have been a number of identified 
conditions that have been shown to increase the risk 
with developing a rhabdomyosarcoma along with other 
tumours: 
• Li-Fraumeni syndrome 
• Pleuropulmonary blastoma 
• Neurofibromatosis type 1 (NF1) 
• Beckwith-Wiedemann syndrome 
• Costello syndrome 
• Noonan syndrome [30] 
The most common locations for development of 
rhabdomyosarcoma are the head and neck including 
parameningeal sites (including the nasopharynx, 
middle ear, paranasal sinuses), and the genitourinary 
tract including bladder, prostate, vagina, vulva, uterus, 
and paratesticular regions [31] (Table 6). 
Table 6:  Most Common Locations for Development of 
Rhabdomyosarcoma 
Site of Primary Tumour Incidence 
Parameningeal 16 
Orbit 10 
Head/Neck 10 
Genitourinary (All) 23 
Extremity 19 
Other 22 
Table Adapted from The Liddy Shriver Sarcoma Initiative [31]. 
Patients present with signs and symptoms that 
depend on the site of the tumour listed in Table 7. 
Table 7: Signs and Symptoms for Tumour 
Site of primary tumour Signs/Symptoms 
Trunk, limbs, groin • a mass or swelling  
• may or may not be painful 
Eye • the eye can bulge out  
• strabismus 
Ear, nasal sinuses • headache 
• earache 
• sinus congestion 
Bladder, prostate • haematuria 
Vagina • vaginal bleeding 
Abdomen, pelvis • abdominal pain 
• vomiting 
• constipation 
Bile ducts • jaundice 
Table Adapted from The American Cancer Society [32]. 
Imaging used in the diagnostic process includes X-
rays, MRI, and CT scans. A biopsy of the tumour will 
be taken, either via surgery or a needle procedure, and 
the diagnosis will be confirmed by a pathologist. Once 
the type of rhabdomyosarcoma has been determined, 
further imaging will be taken, including bone scans, to 
look for the presence of metastases and stage the 
disease. Finally, the patient will be placed into a clinical 
group along with being stratified into a risk category 
that determines their treatment regimen and the 
aggressiveness of this treatment. 
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The risk group that patients are assigned differen-
tiates the 5-year survival rates for rhabdomyosarcoma 
(Table 8). 
Table 8:  5-Year Survival Rates in Rhabdomyosarcoma 
in Risk Group Patients 
Risk group 5-year survival rate 
Low Risk for children, survival rate is over 90% 
Intermediate Risk survival rates range from 60-80% 
High Risk survival rates range from 20-40% 
Table Adapted from The American Cancer Society [33].
 
As with other types of cancer, the treatment for 
rhabdomyosarcoma follows a similar regimen of neo-
adjuvant chemotherapy, surgery to remove the rumour, 
adjuvant chemotherapy with or without radiotherapy, 
and potential further surgery to remove any 
metastases.  
2. RESULTS 
There were 56 paediatric patients included in this 
study in the timeframe from 2001 to 2008. The patients 
were selected on the basis of a diagnosis of either 
osteosarcoma, Ewing’s sarcoma, or rhabdomyo-
sarcoma (Table 9).  
2.1. Osteosarcoma Treatment 
 
 
Table 9:  Detailed Results of 56 Paediatric Patients included in this Study in the Timeframe from 2001 to 2008 
 Osteosarcoma 
Ewing’s 
Sarcoma 
Alveolar 
Rhabdomyosarcoma 
Embryonal 
Rhabdomyosarcoma 
No. of patients 11 24 10 11 
Male 7 10 - - 
Female 4 14 - - 
Age range 4-16 1-16 - - 
Mean age 10 12 - - 
Overall survival (%) 64 71 80 73 
Event free survival (%) 55 58 60 73 
Primary site of disease (%) 
Femur: 47 
Tibia: 41 
Humerus: 5.5 
Scapula: 5.5 
Other: 1 
Pelvis: 29 
Femur: 22 
Paraspinal: 16 
Chest wall: 10 
Tibia: 10 
Other: 13 
- - 
Metastatic rate (%) 27 21 20 0 
Overall survival with metastases (%) 0 40 100 n/a 
Event free survival with metastases (%) 0 40 100 n/a 
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2.2. Ewing’s Sarcoma Treatment 
 
2.3. Rhabdomyosarcoma Treatment 
 
 
3. DISCUSSION 
3.1. Overall Survival and Event-Free Survival 
In the period from 2001 through to October 2008, 
there were 11 patients diagnosed with Osteosarcoma. 
7 of these patients survived for more than five years 
and only one had disease recurrence providing an 
overall survival of 64% and event-free survival of 55%. 
This compares to other UK studies putting overall 
survival at 59% and a European rate at 66% [34]. In the 
metastatic group there were 3 patients all of whom 
died, giving an overall survival rate of 0%. 
In this same period there were 24 patients 
diagnosed with Ewing’s Sarcoma of which 17 lived 
longer than 5 years and 7 died giving an overall 
survival of 71%. 14 of the surivors have had no disease 
recurrence and therefore there is an event-free survival 
of 58%. Yorkhill’s overall survival rate is comparable to 
UK (55%) and European (62%)
 
studies [34]. In the 
metastatic group there were 5 patients, 2 of which 
survived past 5 years giving an overall survival rate of 
40%. 
There were 10 Alveolar Rhabdomyosarcoma 
patients with 80% surviving and an Event-Free Survival 
of 60%. UK figures give a 65% overall survival rate for 
this subtype of rhabdomyosarcoma [35]. There were 2 
patients with metastatic disease, both of whom 
survived past 5 years with no disease recurrence giving 
an overall survival and event free survival of 100%. 
There were 11 Embryonal Rhabdomyosarcoma 
patients with an overall survival of 73% and all of those 
survivors were event-free. UK figures give an 82% 
overall survival rate for this subtype of 
rhabdomyosarcoma [35].  
Gender 
For osteosarcoma, the overall survival rate for 
males is 57% with an event-free survival of 43%, 
compared to an overall survival for females of 75% with 
an event-free survival of 75%. Osteosarcoma has a 
more favourable prognosis with girls and the data 
reflects this [15]. The close relationship with growth and 
the fact that males have a growth spurt at an older age 
is the most likely reason for this prognostic indicator.  
For Ewing’s sarcoma, the overall survival rate for 
males is 80% with an event-free survival of 70%, 
compared to an overall survival for females of 64% with 
an event-free survival of 64%. 
Treatment Type 
For osteosarcoma, one of the main prognostic 
indicators is response to initial chemotherapy. A ‘good’ 
response is defined as one where there is at least 90% 
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necrosis of the tumour when examined by the 
pathologist after neo-adjuvant therapy. From our data, 
67% of the osteosarcoma patients were judged to have 
a poor response to their initial chemotherapy.  
In our sample there was a 67% overall survival rate 
in good responders compared to 50% of poor 
responders. 
Regarding surgery type, the most common type of 
surgery performed was a limb salvage operation with 
58% of patients opting for this. Understandably patients 
want to avoid amputation as best they can but this 
must be a balancing act between the risks of salvaging 
a limb versus the risk of not excising the entire tumour.  
The 5-year survival rate in our group of patients that 
underwent limb salvage surgery was 66.7%.  
Only 1 patient underwent amputation before 2008 
and has had an event free survival of more than five 
years. Due to the small sample sizes, it is difficult to 
draw any solid conclusions in our data from limb-
salvage vs. amputation. 
Looking at the type of surgery performed for 
Ewing’s patients, the most common was to elect for no 
surgery at all. This was due to a variety of reasons 
including difficult position of the primary tumour and 
disease that was cured by chemotherapy and 
radiotherapy only.  
From 2001 to 2008 there is a 100% overall survival 
in those who have undergone limb salvage surgery. All 
of these patients had local disease with no metastases. 
There is a 50% overall survival in those who did not 
undergo any surgery, however, there is only a 30% 
event free survival in that group. 
Looking at the data for rhabdomyosarcoma patients, 
treatment involving surgery versus a non-surgical 
approach was in the ratio of 2:1. There were a wide 
variety of surgical procedures performed depending on 
the site of the original tumour. Sometimes, a non-
surgical approach was favoured especially in patients 
were the tumour was considered non-resectable due to 
its proximity to vital structures. In other cases, some 
patients presented with such poor prognosis that their 
treatment plan was palliative and surgery was 
considered to be inappropriate.  
Radiotherapy was administered in 69% of patients. 
Sometimes this was adjuvant to surgery and 
sometimes this was instead of a surgical procedure. In 
some of the more recent cases, patients travelled to 
Florida to receive radiotherapy in the form of proton 
therapy. Although, to date, there has been no 
published data as to the efficacy of this new treatment 
and whether or not its side effects are less than that of 
conventional radiotherapy.  
SUMMARY 
Our results reflect access to an experienced and 
innovative paediatric sarcoma service with close links 
to a national Sarcoma MDT. The data falls in line with 
other studies in terms of age of onset, location of 
primary tumour, metastatic rate, site of metastases, 
and prognosis for all cancer types. Limb salvage 
surgery is greatly favoured over amputation for both 
osteosarcoma and Ewing’s sarcoma. Females have a 
more favourable prognosis in osteosarcoma and a 
slightly poorer prognosis in Ewing’s sarcoma. Yorkhill’s 
overall survival rates are currently better than the UK-
wide statistic for three of the four tumours examined.  
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